MF Global Upgrades AstraZeneca plc (AZN) to Buy
More News related to AZN
- MedImmune Grants Five New Fellowships to Help Expand Premature Infant Follow-Up Care Research
- AstraZeneca Survey: Physicians Play Critical Role in Helping Patients Take Medicines as Prescribed
- MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
- AstraZeneca (AZN) Receives FDA Approval for Once-Daily SEROQUEL XR(R)
- FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
More News related to Upgrades
- GenCorp's Aerojet (GY) Awarded U.S. Missile Defense Agency Contract
- Epicor Software (EPIC) Board Determines Not to Pursue Elliott Associates' Proposal
- S&P Announces Change to US Index: PPS for LDG
- Law Office Announces Class Action Lawsuit Against AuthenTec (AUTH)
- Capstone Turbine (CPST) Announces New Distributor Agreement with General Detectors International
MF Global upgrades AstraZeneca plc (NYSE: AZN) from Neutral to Buy and raises thier price target from 2350p to 2600p.
AstraZeneca PLC discovers, develops, manufactures, and markets prescription pharmaceuticals, biologics, and vaccines in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide.
Related Categories
UpgradesStocks Mentioned
+3.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
